Videos
Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles
June 29th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and rectifying perverse financial incentives within health care contract structures.
Biosimilar Misconceptions, PBM Transparency, and Value-Based Care: Insights From Canavan & O'Dell
June 15th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain the misconception that cheaper biosimilars automatically lead to lower costs due to pharmacy benefit manager (PBM) spread pricing, while also highlighting major PBM trends toward increased transparency, value-based care, and efforts to reduce prescription costs.
The Global Biosimilar Development and Approval of Yesintek With Elena Wolff-Holz, MD
April 13th 2025Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable efficacy and safety data while noting challenges in global patient recruitment and regulatory navigation.
Enhancing Biosimilar Adoption in Value-Based Oncology Care
February 16th 2025Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for greater payer trust in oncologists’ treatment decisions.
Understanding Biosimilars Through Education and PBM Formulary Perspective
February 2nd 2025Josh Canavan, PharmD, head of pharmacy at RazorMetrics, recommends key educational resources for biosimilars, and emphasizes the extensive research conducted before pharmacy benefit managers (PBMs) add medications, including biosimilars, to their formularies.
